Breakthrough
system for
treating fluid
overload
Discover our non-invasive drug free system and how it is designed to decongest fluid overloaded patients and improve their quality of life
Discover our non-invasive drug free system and how it is designed to decongest fluid overloaded patients and improve their quality of life
Fluid Overload
Fluid overload hospitalizes millions of patients worldwide. It is caused by an excessive build-up of fluids in the interstitial compartment which interferes with the metabolic processes of vital organs.
Left untreated, fluid overload can cause serious complications, affecting patients’ ability to perform daily activities such as walking, sleeping or even breathing.
Current in-hospital treatments, such as diuretics, aim to facilitate the kidney’s ability to secrete large volumes of urine and reduce the “overload”.
These treatments often require invasive administration of the drugs and may lead to adverse effects, such as deterioration of kidney renal function, electrolytes imbalance and progressive resistance to therapy.
What if there is a better way…
The AquaPass Solution
AquaPass is an early-stage medical device startup aiming to revolutionize the way fluid overload is treated today.
Aquapass offers the first non-invasive, drug-free, fluid overload treatment system. The system removes fluids directly from the interstitial compartment, through the skin, by controlling and enhancing the natural process of perspiration.
Our award-winning, patented system is composed of a wearable body suit and its microclimate generator. This creates the optimal environmental conditions to induce natural perspiration and its immediate evaporation thus ensuring the patient is dry and without thermal discomfort.
The system maintains a stable core temperature while enabling treatment to be optimized per individual’s physiology. This highly efficient and safe treatment can be provided in hospital, at outpatient clinics and at home.
AquaPass Advantages
non-invasive
Drug-free
treatment
Safe & easy-to-use
in and out
of hospital
Relief of overload
symptoms and
preservation of
renal function
Minimal
side effects
Hear From One of Our Patients
About AquaPass
Our Management
Yaacov Nitzan
Founder & CTO
Or Inbar
Head of R&D
Gali Vino
Director Clinical &
Regulatory Affairs
Board of Directors
Alon Maor
Life science investor, BRM
Tovy Sivan
Director & Co-founder of medical device companies
Moshe Mizrahy
Successful entrepreneur and medical veteran
Adi Gur
CEO, Arbelon holding company (medtech consulting)
Scientific Advisory Board
Ohio State University
Professor
Doron Aronson
Rambam Medical Center
Professor
Daniel Burkhoff
Cardiovascular Research Foundation
New York, NY
News & Events
AquaPass
Successfully
Completes Proof
of Concept Study
October 10, 2021
